Medicine May Plunge Back into The Dark Ages

554

Medicine

Scientists found that bacteria gets resistant to drugs used when all other treatments have failed, puts the world on the cusp of a “post-antibiotic era”.

The  Lancet magazine says that even the powerful antibiotic like colistin is resisted by bacteria in patients and livestock in China.  Scientists describe a new mutation, dubbed the MCR-1 gene, that prevented colistin from killing bacteria.

This means bacteria is  fast becoming completely resistant to treatment.  

Dangers :

  • Common infections would kill once again
  • Surgeries and cancer therapies, which are reliant on antibiotics, would be under threat.
  • The new resistance gene will hook up with others plaguing hospitals, leading to bacteria resistant to all treatment – what is known as pan-resistance.
  • The resistance had spread between a range of bacterial strains and species, including E. coli, Klebsiella pneumoniae and Pseudomonas aeruginosa
  • There is also evidence that it has spread to Laos and Malaysia.

Prof Timothy Walsh, who collaborated on the study, from the University of Cardiff, told the BBC News website: All the key players are now in place to make the post-antibiotic world a reality.

If MRC-1 becomes global, which is a case of when not if, and the gene aligns itself with other antibiotic resistance genes, which is inevitable, then we will have very likely reached the start of the post-antibiotic era.

“At that point if a patient is seriously ill, say with E. coli, then there is virtually nothing you can do.”

Antibiotic Action :

  • Prof Walsh is meeting both the agricultural and health ministries this weekend to discuss whether colistin should be banned for agricultural use.
  • Prof Laura Piddock, from the campaign group Antibiotic Action, said the same antibiotics “should not be used in veterinary and human medicine”.
  • Look out for alternative treatment options.
  • Start looking at combinations of antibiotics that may still be effective.

BBC Credit Link

LEAVE A REPLY